In a recent case series, the effectiveness of Acesso Biologics’ Amniotic Grafts was carefully examined as a covering on stubborn chronic wounds, including Diabetic Foot Ulcers (DFU), Venous Leg Ulcers (VLU), and Pressure Ulcers (PU). Ten patients, each facing significant healing challenges, were treated with a combination of Acesso Biologics’ advanced graft technology and Standard of Care (SOC) practices.

The study’s findings were compelling. Over the course of treatment, which ranged from 4 to 54 weeks, all patients achieved full wound closure! One of the standout cases involved a patient with a diabetic foot ulcer that had shown little improvement with previous treatments. After integrating the amniotic grafts into their care plan, the patient’s wound began to heal more rapidly, eventually closing completely—something that had previously seemed out of reach.

These findings align with the innovative approach Acesso Biologics takes in developing advanced wound care solutions. The success observed in this study reinforces the role of our amniotic grafts in achieving faster and more effective healing in difficult cases. As we continue to focus on improving patient outcomes, this case serves as a powerful example of how our products can be an integral part of effective treatment strategies for chronic wounds.